Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H21F3N4O4 |
| Molecular Weight | 474.4324 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(N=C1)N2[C@@H](CO)COC3=C2C=CC=C3C(=O)NC4=CC=C(OCC(F)(F)F)N=C4
InChI
InChIKey=QZUCKCLSVBFSOS-INIZCTEOSA-N
InChI=1S/C23H21F3N4O4/c1-14-5-7-19(27-9-14)30-16(11-31)12-33-21-17(3-2-4-18(21)30)22(32)29-15-6-8-20(28-10-15)34-13-23(24,25)26/h2-10,16,31H,11-13H2,1H3,(H,29,32)/t16-/m0/s1
| Molecular Formula | C23H21F3N4O4 |
| Molecular Weight | 474.4324 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:40:24 GMT 2025
by
admin
on
Tue Apr 01 16:40:24 GMT 2025
|
| Record UNII |
2TM92XK3YA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2TM92XK3YA
Created by
admin on Tue Apr 01 16:40:24 GMT 2025 , Edited by admin on Tue Apr 01 16:40:24 GMT 2025
|
PRIMARY | |||
|
CHEMBL3545228
Created by
admin on Tue Apr 01 16:40:24 GMT 2025 , Edited by admin on Tue Apr 01 16:40:24 GMT 2025
|
PRIMARY | |||
|
942614-99-5
Created by
admin on Tue Apr 01 16:40:24 GMT 2025 , Edited by admin on Tue Apr 01 16:40:24 GMT 2025
|
PRIMARY | |||
|
23628017
Created by
admin on Tue Apr 01 16:40:24 GMT 2025 , Edited by admin on Tue Apr 01 16:40:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Japan Tobacco; Class: Analgesic; Mechanism of Action: TRPV1 receptor antagonist; Highest Development Phases: Discontinued for Overactive bladder, Pain; Most Recent Events: 28 Jul 2011 Discontinued - Phase-II for Pain in Japan (PO), 28 Jul 2011 Discontinued - Phase-II for Overactive bladder in Japan (PO), 29 Jul 2010 Phase-II clinical trials in Pain in Japan (PO)
|
||
|
ACTIVE MOIETY |
JTS-653 displaced (3H)resiniferatoxin binding to human and rat TRPV1. JTS-653 competitively antagonized the capsaicin-induced activation of human TRPV1 with pA2 values of 10.1. JTS-653 also inhibited proton-induced activation of human and rat TRPV1 with IC50 values of 0.320 and 0.347 nM, respectively. JTS-653 significantly prevented capsaicin-induced mechanical hyperalgesia at 1 mg/kg p.o. and attenuated carrageenan-induced mechanical hyperalgesia at 0.3 mg/kg p.o. JTS-653 significantly attenuated carrageenan-induced thermal hyperalgesia at 0.1 mg/kg p.o. and fully reversed at 0.3 mg/kg p.o. without affecting the volume of the carrageenan-treated paw.
|